Navigation Links
PROGNOSIS Extends its Popular IP Telephony Management Software to Support Nortel Environments
Date:3/18/2008

ORLANDO, Fla., March 18 /PRNewswire/-- VoiceCon 2008, Integrated Research (ASX: IRI), developers of PROGNOSIS performance monitoring and management solutions, today announced the official launch of support for Nortel IP communications technology through version 9.5 of its market-leading PROGNOSIS IP Telephony Manager software.

This expanded functionality now means that PROGNOSIS is the only specialized IP telephony management solution on the market supporting multi- vendor environments where Nortel, Avaya and Cisco systems co-exist. Filling a gap not covered by traditional PBX administration, network management and event management tools, PROGNOSIS has become the provider of choice for the world's largest enterprises and service providers since its introduction in 2000.

This new development gives PROGNOSIS an opportunity to address the combined install base for the world's 3 largest enterprise IP telephony vendors: Cisco, Avaya and Nortel. It also provides a highly attractive solution for the increasing number of large organizations faced with the challenge of managing a multi-vendor deployment.

"Many organizations are supporting multi-vendor IP-PBX systems to maintain vendor independence, or as a byproduct of the inheritance of legacy systems," said Mark Brayan, CEO of Integrated Research. "We have a management tool that gives a single, unified view across an organization's entire IP telephony environment. By adding Nortel, we can now support more customers and gain access to a new set of market opportunities."

Product Manager for IP telephony, John Dunne and his team will be on hand at VoiceCon 2008 in Orlando to demonstrate the latest version of PROGNOSIS and provide further information on this new development.

PROGNOSIS Benefits:

For homogeneous Nortel environments, PROGNOSIS IP Telephony Manager 9.5 provides real-time monitoring and management in critical areas such as voice quality, device status and utilization as well as system performance and fault notification.

The benefit of using PROGNOSIS in a mixed Nortel environment with Avaya and/or Cisco is that operations staff are given a single, unified view across all their disparate IP telephony environments. PROGNOSIS also eliminates the cost prohibitive exercise of procuring and maintaining multiple IP telephony management tools as well as reducing staff training times.

MSP clients benefit by being able to extend a common service-level offering to all of their customers, regardless of their IP communication platform.

Compatibility:

PROGNOSIS IP Telephony Manager 9.5 supports Nortel CS1000 models E, S and M running Communication Server 4.0, 4.5 or 5.0.

Pricing:

PROGNOSIS IP Telephony Manager 9.5 is priced on a per-phone basis for both enterprise and managed service provider customers. List pricing begins at $50 per phone with discounts applied based on volume and duration of the license term.

About PROGNOSIS and Integrated Research

Integrated Research (ASX: IRI) - the people behind PROGNOSIS - is a publicly listed software company with a 20-year heritage of providing precise performance monitoring solutions for business-critical computing and IP telephony environments.

The company services customers in more than 50 countries through direct sales offices in the USA, Europe and Australia, and via a global channel- driven distribution network.

Customers include the world's largest bank, telecommunications company, stock exchange and computer hardware manufacturer.
For more information visit the PROGNOSIS website: http://www.prognosis.com

Media contact:

Belinda York

Vice President Global Marketing

PROGNOSIS - by Integrated Research

t: +61 (2) 9921 1565

e: belinda.york@prognosis.com

w: http://www.prognosis.com


'/>"/>
SOURCE PROGNOSIS
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Obesity Linked to Poor Prognosis for Some Breast Cancer Patients
2. Protein Linked With Poor Prognosis in Early-Stage Breast Cancer
3. MicroRNAs May Predict Colon Cancer Prognosis
4. Smoking Worsens Prognosis for IPF Patients
5. Smoking belies milder disease but worse prognosis for IPF patients
6. UAB research could improve the prognosis and treatment of lung cancer
7. Scoring system identifies MDS patients who have low-risk disease but a poor prognosis
8. MammaPrint(R) Breast Cancer Test Shown To Be Powerful Tool for Prognosis Prediction in Postmenopausal Breast Cancer Patients
9. Agendias MammaPrint(R), the Only FDA-Cleared Breast Cancer Prognosis Test, is Now Widely Available to U.S. Patients
10. Test gives insight into prognosis in patients with plasma cell malignancies, finds Mayo Clinic study
11. Using additional biopsy-scoring data may help determine prostate cancer prognosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology: